Related Experiment Videos
[Parkinson's disease and glutamatergic system]
Yu S Mironova1, N G Zhukova1, I A Zhukova1
1Siberian State Medical University, Tomsk, Russia.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|June 22, 2018
Summary
Parkinson's disease (PD) involves non-motor symptoms and multiple neurotransmitter systems, not just dopamine. Glutamate excitotoxicity may play a key role in PD initiation and progression, suggesting new treatment avenues.
Area of Science:
- Neuroscience
- Neurology
- Pathology
Background:
- Parkinson's disease (PD) presents with diverse non-motor symptoms preceding motor deficits.
- Pathological changes in PD are detectable early via neuroimaging and genetic studies.
- PD is increasingly viewed as a systemic disease affecting multiple neurotransmitter systems.
Purpose of the Study:
- To investigate the role of the glutamatergic system in the initiation of neurodegeneration in Parkinson's disease.
- To explore glutamate's dual function as a neurotransmitter and neurotoxin in PD pathogenesis.
- To discuss the implications of glutamate excitotoxicity for PD treatment strategies.
Main Methods:
- Review of neuroimaging, pathomorphological, and genetic studies.
- Analysis of the role of neurotransmitter systems beyond dopaminergic.
- Discussion of glutamate's function in neurodegeneration and clinical manifestation progression.
Main Results:
- Non-motor symptoms are prominent early features of Parkinson's disease.
- The glutamatergic system, alongside dopaminergic, is implicated in PD pathogenesis.
- Glutamate acts as both a neurotransmitter and a neurotoxin in the context of PD.
Conclusions:
- Understanding glutamate excitotoxicity in PD is crucial for developing improved treatment tactics.
- Targeting the glutamatergic system may offer novel therapeutic approaches for Parkinson's disease.
- Further research into glutamate excitotoxicity could lead to better pathogenetic therapies for PD.